The market is closely watching the overseas development of Burning Rock Biotech Ltd. Sponsored ADR Class A (BNR.US), whose stock price has nearly doubled, entering a period of consolidation.

With the cooperation between Burning Rock Biotech Ltd. Sponsored ADR Class A (BNR.US) and MGI Tech Co., Ltd., as well as the disclosure of Burning Rock Biotech Ltd. Sponsored ADR Class A's own financial report for the third quarter of 24Q3, Burning Rock Biotech Ltd. Sponsored ADR Class A experienced a rapid upward trend in November and December this year. It was observed that on December 5th, the intraday stock price of Burning Rock Biotech Ltd. Sponsored ADR Class A reached as high as 7.47 US dollars, returning to the level in late July, filling the price decline in the third quarter of this year. This round of trend started on November 5th, and within a month, the stock price of Burning Rock Biotech Ltd. Sponsored ADR Class A has increased by 1.76 times. However, after December 5th, the upward momentum of Burning Rock Biotech Ltd. Sponsored ADR Class A's stock price seemed to come to a halt and entered a sideways trend. As of the Christmas holiday, Burning Rock Biotech Ltd. Sponsored ADR Class A has been in a sideways period for 13 trading days, and its future trend has undoubtedly become a focus of investors' attention. Brief balance after the upward trend Looking back at the upward trend of Burning Rock Biotech Ltd. Sponsored ADR Class A in November, it is more accurate to say that the market was trended by the main capital opening up the upward space under multiple positive catalysts. It can be observed that this round of upward movement of Burning Rock Biotech Ltd. Sponsored ADR Class A has a more obvious characteristic, that is, the rise without volume. If we extend the time to September 20th of this year, it is not difficult for investors to see that after the decline in August and September, the liquidity-lacking Burning Rock Biotech Ltd. Sponsored ADR Class A had reached the edge of liquidity exhaustion at this time, with a daily trading volume of only 2623 shares and a turnover rate of only 0.03%. However, starting from the next day, a stream of capital began to gradually flow into Burning Rock Biotech Ltd. Sponsored ADR Class A. On September 23rd, the company's trading volume slightly increased to 17,000 shares, although the company's stock price fluctuated slightly over the following month, the daily trading volume remained at around 10,000 shares. On October 4th, October 11th, and October 14th, the daily trading volume of Burning Rock Biotech Ltd. Sponsored ADR Class A also reached 321,500 shares, 426,100 shares, and 246,300 shares respectively, with turnover rates of 3.13%, 4.15%, and 2.40% respectively, showing significantly higher trading activity than before. As mentioned earlier, at this time Burning Rock Biotech Ltd. Sponsored ADR Class A was in a bottom consolidation stage, and after a long period of decline, the volume had gradually decreased to the bottom. The stock price fluctuated smaller and smaller, with weak trading and little attention. At this time, the volume suddenly increased, and after a few trading days, it significantly increased. It can be seen that on October 4th, the intraday stock price of Burning Rock Biotech Ltd. Sponsored ADR Class A broke through the previous high to reach $5.65, after breaking the previous high with large volume, it retraced the previous high with small volume. Generally speaking, this is a signal of the main capital entering the market, marking the start of the main capital's involvement. However, when the volume of Burning Rock Biotech Ltd. Sponsored ADR Class A broke through again on October 11th, its main capital did not choose to raise directly, but continued to absorb at the lower edge of the box, until around November 5th when news of Burning Rock Biotech Ltd. Sponsored ADR Class A's cooperation with MGI Tech Co., Ltd. to expand internationally, causing the stock price to start rising. During the price surge in November, the main capital of Burning Rock Biotech Ltd. Sponsored ADR Class A changed its gradual style and chose a rapid upward trend strategy by continuously pulling out large positive candles during the rise. Generally, the main capital using a rapid upward trend strategy has strong financial strength and has collected enough chips at low levels, achieving a high level of control over the market. For example, on November 27th and November 29th, with a daily trading volume of only 22,816 shares and 20,225 shares, respectively, the stock price of Burning Rock Biotech Ltd. Sponsored ADR Class A rose significantly by 25.12% and 16.12%, showing the high level of control of the main capital. It can be seen that during this round of rise, the main capital basically did not choose a significant retreat or shake the market during the process. This allowed the stock price of Burning Rock Biotech Ltd. Sponsored ADR Class A to skyrocket within a month, saving the main capital's funds, shortening the duration of the rise, and opening up the upward space. However, it is worth noting...Yes, the recent rise of Burning Rock Biotech Ltd. Sponsored ADR Class A did not come with high trading volume. Although the company's daily trading volume was above 40,000 shares from November 5th to 7th at the beginning of the market rally, the highest daily trading volume during the entire uptrend was only 70,088 shares, much lower than the 426,100 shares seen in October. With the lack of increased volume, Burning Rock Biotech Ltd. Sponsored ADR Class A entered a sideways consolidation phase after December 5th. On December 23rd, the trading volume of the company's stock fell again to 6,183 shares.From the perspective of stock performance, it is currently moving away from the previous cost range, and such volume is far from achieving the goal of profit realization. Overall, the stock of Burning Rock Biotech Ltd. Sponsored ADR Class A11 has shown a significant volume increase in November, which to a certain extent confirms that institutional funds have entered, the chips are locked in well, and the stock price is being pushed up. The subsequent decrease in volume and sideways movement may indicate that institutional funds currently have no intention to sell, only a temporary shakeout, with a high probability of trend continuation, investors may continue to be bullish on the future. "The milestone of going global" release may be a key point for stock price increase. It was understood that Burning Rock Biotech Ltd. Sponsored ADR Class A initially promoted its "in-hospital + out-of-hospital" dual-wheel growth model at the beginning of its listing, but as the business gradually deepened, Burning Rock Biotech Ltd. Sponsored ADR Class A's business focus in recent years has shifted completely to the in-hospital model. In its view, the in-hospital model has incomparable competitiveness. In previous financial reports, Burning Rock Biotech Ltd. Sponsored ADR Class A mentioned that "once the in-hospital laboratory, equipment, and systems are in place, we will regularly sell them our reagent kits, thus creating high barriers to entry and high customer loyalty." In other words, Burning Rock Biotech Ltd. Sponsored ADR Class A believes that the in-hospital model business is more stable, and the profit margin may also be higher. Since the second half of 2022, Burning Rock has been vigorously promoting the in-hospital channel, and the revenue gap between in-hospital and out-of-hospital business has gradually narrowed. In the third quarter of 2023, the company's in-hospital channel revenue surpassed the out-of-hospital channel for the first time. In the first and second quarters of this year, its in-hospital channel revenue has stabilized at around 55%. Just when the market thought that its in-hospital business growth was stalling, the recently disclosed 24Q3 financial report of the company showed continued progress. Data shows that in the third quarter of 2024, Burning Rock Biotech Ltd. Sponsored ADR Class A's in-hospital testing revenue was 63.77 million yuan, a year-on-year increase of 17.0% and a quarter-on-quarter increase of 6.5%. In contrast, in the third quarter of 2024, the earnings of Burning Rock Biotech Ltd. Sponsored ADR Class A's central laboratory testing were 39.98 million yuan. Thanks to the continuous cost control measures in recent quarters, the profit situation of Burning Rock Biotech Ltd. Sponsored ADR Class A has also improved to a certain extent. In the third quarter, Burning Rock Biotech Ltd. Sponsored ADR Class A achieved a revenue of 129 million yuan, a year-on-year increase of 1%. After deducting Non-GAAP gross profit for Non-GAAP sales and general administrative and management expenses, a profit of 25.2 million yuan was realized this quarter. So far, Burning Rock Biotech Ltd. Sponsored ADR Class A has achieved profitability for three consecutive quarters (Non-GAAP GP-SG&A), and it is showing a continuous upward trend. Although the company continues to adjust its business development strategy, it has still failed to expand its business cake. Burning Rock Biotech Ltd. Sponsored ADR Class A set a goal of at least 20% growth in annual revenue at the beginning of 2023, but ultimately failed to achieve it. In 2023, the company's total revenue was 537 million yuan, a decrease of 4.58% compared to 563 million yuan in 2022. In this context, going global is particularly important for Burning Rock. According to a new market research by The Insight Partners, the global genetic testing services market is growing significantly due to the increasing incidence of surgical site infections. It is predicted that the global genetic testing services market will increase from $38.6 billion in 2022 to $124.8 billion in 2030, with a compound annual growth rate of 15.8%. In terms of regional growth, the genetic testing services market in the Asia-Pacific region reached $650 million in 2022 and is expected to reach $2.16 billion by 2030; the European genetic testing services market reached $930 million in 2022 and is expected to reach $2.78 billion by 2030; and the North American market is expected to reach $4.98 billion in 2030. For Burning Rock Biotech Ltd. Sponsored ADR Class A, which is still in the "standstill" stage, the "tailwind" of MGI Tech Co., Ltd.'s global expansion is undoubtedly a boon for Burning Rock, which urgently needs to "expand the cake". Financial reports show that the company's current revenue from pharmaceutical company collaborations is 24.9 million yuan, a year-on-year increase of 27.1%; in addition, in the current period, Burning Rock Biotech Ltd. Sponsored ADR Class A successfully passed three CAP interlaboratory evaluations and has cumulatively passed more than 270 interlaboratory evaluations organized by domestic and foreign authoritative institutions. This is also critical for accelerating the landing of its advanced diagnostic technology in clinical practice and speeding up its global expansion. From the perspective of cash flow, as of September 30, Burning Rock Biotech Ltd. Sponsored ADR Class A had cash and cash equivalents...Fixed assets, restricted cash and short-term investments total approximately RMB 498 million, which should be able to support its research and operations for the next three years.Je suis dsol, je ne comprends pas.